COVID-19 Infection and Autoimmune Link and Your Genetics

COVID-19 Infection and Autoimmune Link: Genetic Susceptibility

What is COVID-19 Infection and Autoimmune Link?

The relationship between COVID-19 infection susceptibility and autoimmune predisposition is one of the more compelling discoveries to emerge from the pandemic era of genetic research. While most people understand that exposure to SARS-CoV-2 is the primary driver of infection, a growing body of evidence suggests that an individual's genetic makeup can influence how the immune system responds at first contact with the virus — and whether that immune response carries overlap with pathways associated with autoimmune conditions such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

This page covers the genetic architecture underlying COVID-19 infection susceptibility and its shared biology with autoimmune risk. It is distinct from genetic factors associated with COVID-19 severity — that is, how severely the disease progresses after infection has already occurred. Here, the focus is on the genetic landscape influencing who is more susceptible to acquiring the infection in the first place, and how those same genetic variants intersect with immune pathways relevant to autoimmune conditions.

Understanding this intersection matters because the immune system does not operate in isolated compartments. Genes that govern antigen presentation, interferon signaling, and immune cell recruitment are relevant both to frontline antiviral defense and to the self-directed inflammation that characterizes autoimmune disease. Shared genetic architecture between COVID-19 susceptibility and autoimmune conditions suggests that some individuals may carry variants that simultaneously shape their vulnerability to viral infection and their baseline immune tone.

The genetics behind COVID-19 Infection and Autoimmune Link

Several gene families emerge consistently from cross-trait genetic analyses examining COVID-19 susceptibility alongside autoimmune conditions. The most prominent involve interferon signaling, antigen presentation via the major histocompatibility complex (MHC), and immune cell trafficking.

IFNAR2 (also referenced in some analyses alongside the nearby IFNAR2-IL10RB locus) encodes a subunit of the interferon alpha and beta receptor. This receptor is a cornerstone of the innate antiviral immune response. When a cell encounters a virus, it releases type I interferons, which bind to IFNAR2-containing receptor complexes and trigger a cascade that puts neighboring cells into an antiviral state. Variants in this region have been associated with altered COVID-19 susceptibility, and the same interferon pathway has long been implicated in autoimmune diseases, where dysregulated interferon signaling can drive aberrant immune activation against self-tissue.

HLA-DQA1 and HLA-DRB1 are members of the human leukocyte antigen (HLA) system, specifically MHC class II genes. These genes encode proteins that present peptide fragments — derived from both pathogens and self-proteins — to CD4+ T helper cells. The specificity of this antigen presentation is partly determined by which HLA alleles a person carries. Certain HLA variants influence how efficiently viral peptides from SARS-CoV-2 are presented to the immune system, and many of the same alleles are classical risk factors for autoimmune diseases including RA and SLE. This overlap is not coincidental: it reflects the central role of antigen presentation in both pathogen defense and autoimmune pathogenesis.

CCR2, the C-C chemokine receptor type 2, binds the chemokine MCP-1 (also known as CCL2) and mediates the migration of monocytes and T cells into inflamed tissues. During viral infection, monocyte recruitment to sites of infection is an essential part of the immune response. CCR2 variation can influence the magnitude and timing of this recruitment, with downstream consequences for both infection control and inflammation. Elevated CCR2-mediated monocyte trafficking is also observed in autoimmune inflammatory contexts, providing another mechanistic bridge between infection susceptibility and autoimmune predisposition.

HLA-B, an MHC class I gene, plays a complementary role in presenting viral peptides to CD8+ cytotoxic T cells, which are responsible for killing virus-infected cells. Specific HLA-B alleles have been associated with differential COVID-19 outcomes and are established factors in autoimmune susceptibility.

Additional genes in the authorized set — including GSDMB, which is involved in pyroptosis and inflammatory cell death, LTA (lymphotoxin alpha), a cytokine with roles in lymphoid tissue organization and immune signaling, GBGT1, involved in glycolipid biosynthesis on cell surfaces, and EFNA3, an ephrin ligand involved in cell adhesion and migration — represent additional nodes in the complex immune network that cross-trait analyses have implicated in the shared architecture between COVID-19 susceptibility and autoimmune conditions.

What the research says

Research base: Moderate.

The scientific foundation for this trait comes from a 2023 study by Yao and colleagues, which applied genome-wide cross-trait analysis and bidirectional Mendelian randomization to examine the shared genetic architecture between rheumatoid arthritis, systemic lupus erythematosus, and COVID-19 outcomes [1]. This approach is methodologically rigorous because Mendelian randomization uses genetic variants as natural instruments to probe causal relationships, reducing confounding from lifestyle or environmental factors that can complicate observational studies.

Cross-trait GWAS analysis identified substantial shared genetic architecture between autoimmune conditions (RA and SLE) and COVID-19 susceptibility, with multiple loci — including in the HLA region and interferon pathway genes — contributing to both phenotypes. [1]

The study found that shared genetic signals cluster in biologically meaningful pathways: interferon alpha and beta receptor signaling (centered on the IFNAR2 locus), MHC antigen presentation (HLA-DQA1, HLA-DRB1, HLA-B), and immune cell trafficking (CCR2). These findings reinforce the hypothesis that autoimmune predisposition and COVID-19 susceptibility are not genetically independent — they draw on overlapping molecular machinery.

Bidirectional Mendelian randomization analyses in the Yao 2023 study suggested evidence for potential causal pathways linking autoimmune genetic architecture to COVID-19 susceptibility outcomes, though effect sizes and directionality varied by outcome and autoimmune condition examined. [1]

It is important to contextualize what this evidence tier means. A moderate confidence rating reflects that while the cross-trait GWAS and Mendelian randomization methodology is robust, the specific effect sizes for individual variants in diverse populations, the precise causal directionality of all identified pathways, and the degree to which these genetic findings translate into clinically meaningful susceptibility differences across real-world exposure conditions all remain areas of active investigation. Readers interested in the analytical approach ExomeDNA uses to evaluate genetic evidence can consult the methodology page for a full explanation of confidence tiers and evidence weighting.

The field of COVID-19 host genetics has advanced rapidly, with large-scale initiatives such as the COVID-19 Host Genetics Initiative contributing genome-wide association data from hundreds of thousands of individuals. The shared architecture findings from Yao 2023 are consistent with signals emerging from these broader efforts, lending additional plausibility to the gene-level associations described on this page.

How COVID-19 Infection and Autoimmune Link affects you

Genetics is one layer of a complex system. For COVID-19 infection susceptibility, the dominant determinants are behavioral and environmental: proximity to infected individuals, vaccination status, masking practices, ventilation in shared spaces, and underlying respiratory or immune health. Genetic variants in the loci described on this page do not override these factors — they represent a background influence on immune system readiness and tone.

For populations carrying certain variants in HLA-DQA1, HLA-DRB1, or the IFNAR2 locus, the immune system's initial response to SARS-CoV-2 exposure may differ in speed, magnitude, or character compared to those carrying alternative alleles. A less efficient interferon response mediated through IFNAR2 variants, for instance, could mean the innate immune alarm system is slower to mobilize, potentially allowing greater initial viral replication before adaptive immunity engages. An HLA profile that presents SARS-CoV-2 peptides less efficiently might affect how quickly T cells recognize and respond to infected cells.

The autoimmune overlap dimension adds another consideration. Those with personal or family histories of autoimmune conditions — particularly RA or SLE — may be carrying HLA haplotypes and immune regulatory variants that, according to cross-trait analyses, also appear at elevated frequency in COVID-19 susceptibility signals. This does not mean that autoimmune conditions themselves cause COVID-19 infection, but rather that the shared genetic architecture suggests common immune pathways are relevant to both.

Vaccination remains the most powerful genetic-agnostic intervention available. Vaccines prime the adaptive immune system in a manner that substantially reduces infection risk across genetically diverse populations, partially compensating for variations in innate immune response speed that genetic variants might influence. For those with known autoimmune conditions or on immunosuppressive therapies, discussion with a clinician about vaccination timing and boosters is especially warranted — those conversations go well beyond what genetic profiling alone can address.

It is also worth noting that the direction of influence in this trait is labeled as detrimental when higher polygenic scores are observed, meaning that the population-level pattern shows those with higher scores for the shared autoimmune-COVID susceptibility architecture tend toward greater susceptibility signals. This is a population-level statistical observation, not a deterministic individual prediction.

Working with your COVID-19 Infection and Autoimmune Link profile

Engaging with a COVID-19 susceptibility and autoimmune link genetic profile starts with understanding what the information does and does not convey. This profile does not predict whether any individual will contract COVID-19. It reflects the degree to which a person's genetic architecture aligns with variants associated, at the population level, with infection susceptibility and shared autoimmune pathways.

For those who receive a profile indicating elevated alignment with these variants, the most actionable responses remain squarely in the domain of established public health practice: maintaining up-to-date vaccination status, including boosters as recommended, attending to indoor air quality and ventilation when in group settings, and discussing immunological health with a primary care provider — particularly if there is a personal or family history of autoimmune conditions.

Clinicians working with patients who have autoimmune conditions and are interested in COVID-19 susceptibility genetics may find this profile useful as a conversational bridge. Immunologists and rheumatologists are increasingly familiar with the HLA literature connecting autoimmune conditions and infectious disease susceptibility, and the IFNAR2 and CCR2 pathways are well-known in clinical immunology. A genetic profile in this area can open a productive dialogue about immune monitoring, vaccination planning, and whether any immunosuppressive therapies in use for autoimmune management require special consideration around infection risk.

People with this profile should not interpret it as requiring specific medical interventions beyond those already recommended for the general population. The profile is an educational tool that can inform conversations with clinicians, not a standalone clinical recommendation.

Related traits and genes

The genetic architecture of COVID-19 susceptibility and autoimmune overlap does not exist in isolation. Several adjacent traits share overlapping gene sets and biological pathways, and understanding the connections can provide a richer picture of immune system genetics.

COVID-19 severity genetic risk covers the genetic determinants of disease progression after infection has occurred — a distinct but related dimension of COVID-19 host genetics. The same HLA loci and interferon pathway genes appear in both susceptibility and severity analyses, but the relative contributions of specific variants differ between these outcomes. Exploring both profiles together provides a more complete view of an individual's COVID-19 immune genetics.

The autoimmune disease risk profile covers the broader genetic landscape associated with susceptibility to autoimmune conditions, with particular emphasis on HLA-DQA1, HLA-DRB1, and HLA-B — genes that appear prominently in both autoimmune GWAS studies and the cross-trait COVID-19 analyses discussed on this page. The mechanistic overlap makes these two profiles natural companions.

The immune function genetics profile provides a broader survey of immune system genetic variation, including pathways involved in innate immunity, cytokine signaling, and immune cell development. CCR2 and IFNAR2 loci covered on this page are part of the larger immune function architecture explored there.

Across categories, the respiratory function genetics profile is relevant because COVID-19 is primarily a respiratory pathogen, and the interface between respiratory epithelial function and immune defense is a key determinant of infection dynamics. Separately, the inflammatory response genetics profile examines the genetic underpinnings of systemic inflammation — a process centrally involved in both COVID-19 pathophysiology and the autoimmune conditions whose genetic architecture overlaps with COVID-19 susceptibility.

Key genes across these related profiles include HLA-DQA1, HLA-DRB1, HLA-B, IFNAR2, CCR2, and LTA — all members of the MHC, interferon, and immune cell trafficking systems that recur throughout immune and autoimmune genetics.

Frequently asked questions

What does it mean to have a higher score on the COVID-19 Infection and Autoimmune Link profile?

A higher score indicates that a person's genetic variants align more closely with patterns associated, in population-level studies, with COVID-19 infection susceptibility and shared autoimmune genetic architecture. It is a statistical signal from population genetics research, not a prediction that any specific individual will contract COVID-19 or develop an autoimmune condition. Exposure, vaccination, and overall health remain the dominant factors in actual infection risk.

Is this profile the same as COVID-19 severity genetics?

No. COVID-19 susceptibility genetics covers factors influencing infection acquisition — who is more likely to contract the virus upon exposure. Severity genetics covers disease course after infection. There is overlap in the gene sets involved, but the two profiles address distinct biological and epidemiological questions. ExomeDNA treats them as separate profiles.

Why do autoimmune genes appear in a COVID-19 susceptibility profile?

The immune system uses the same molecular machinery — antigen presentation via HLA proteins, interferon signaling via IFNAR2, and immune cell trafficking via CCR2 — for both antiviral defense and regulation of self-tolerance. Shared genetic architecture between COVID-19 susceptibility and autoimmune conditions reflects this underlying biological overlap, not a causal relationship between having an autoimmune condition and contracting COVID-19.

Which genes are most important in this profile?

The genes with the strongest biological rationale in this cross-trait context include HLA-DQA1 and HLA-DRB1 for their roles in antigen presentation, IFNAR2 for interferon signaling, and CCR2 for monocyte trafficking. HLA-B contributes through MHC class I antigen presentation to cytotoxic T cells. All of these appear in both COVID-19 host genetics literature and established autoimmune genetics research.

Does vaccination change what this genetic profile means?

Vaccination substantially modifies infection risk across all genetic backgrounds by priming adaptive immune memory before exposure occurs. Genetic variants that affect innate immune response speed — such as IFNAR2 variants affecting interferon signaling — are partially compensated for by vaccine-induced T and B cell memory. The genetic profile reflects baseline immune architecture; vaccination represents a powerful intervention on top of that baseline. Those with autoimmune conditions or on immunosuppressive therapies should discuss vaccination strategy with their clinician.

Can this profile tell me if I have an autoimmune condition?

No. This profile reflects shared genetic architecture between COVID-19 susceptibility and autoimmune conditions at the population level. It is not a tool for assessing whether any individual has or will develop an autoimmune condition. Clinical evaluation, symptom history, and specific autoimmune antibody testing are the appropriate means of evaluating autoimmune conditions.